Review
Nature Reviews Drug Discovery 3, 965-972 (November 2004) | doi:10.1038/nrd1552
Functional genomics to new drug targets
Richard Kramer1 & Dalia Cohen1 About the authors
Abstract
The completion of the sequencing of the human genome, and those of other organisms, is expected to lead to many potential new drug targets in various diseases, and it is predicted that novel therapeutic agents will be developed against such targets. The role of functional genomics in modern drug discovery is to prioritize these targets and to translate that knowledge into rational and reliable drug discovery. Here, we describe the field of functional genomics and review approaches that have been applied to drug discovery, including RNA profiling, proteomics, antisense and RNA interference, model organisms and high-throughput, genome-wide overexpression or knockdowns, and outline the future directions that are likely to yield new drug targets from genomics.
- View At a Glance
Author affiliations
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
Correspondence to: Dalia Cohen1 Email: dalia.cohen@pharma.novartis.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
TCR avidity: it's not how strong you make it, it's how you make it strongNature Immunology News and Views (01 Aug 2001)
RESEARCH
A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteinsNature Immunology Article (01 Jun 2001)
Selectivity of Pyripyropene Derivatives in Inhibition toward Acyl-CoA:cholesterol Acyltransferase 2 IsozymeThe Journal of Antibiotics Original Article
